Stuart L Schreiber

This inventor holds 71 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Cancer Treatment (CPC class A61K). Top assignees: Harvard College, Leland Stanford Junior University, Dana-Farber-Cancer Institute Inc.. Active years: 1982-2024.

USPTO Granted Patents = 71 (Patent Applications = 17)

% Patents Active = 73.2

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 4.3

ph-index = 23

Forward Citations = 1,579(Granted Patents)

Forward Citations (Not Self Cited) = 1,407(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Somerville, MA (US) (1982)
Boston, MA (US) (1992 - 2022)
Cambridge, MA (US) (1998 - 2022)

Company Filing History:

Leland Stanford Junior University

patents

13 out of 1,266

Dana-Farber-Cancer Institute Inc.

patents

4. 8 out of 483

The Broad Institute, Inc.

patents

5. 6 out of 3,071

The General Hospital Corporation

patents

6. 2 out of 8,578

Massachusetts Institute of Technology

patents

7. 1 out of 137

Howard Hughes Medical Institute

patents

8. 1 out of 854

Millennium Pharmaceuticals Limited

Scripps Research Institute

patents

11. 1 out of 7

The Board Institute, Inc.

patents

12. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1982-2024

Loading Chart...

Areas of Expertise:

Cancer Therapy

Histone Deacetylases

Protein Degradation

Inflammatory Bowel Disease

Gluconeogenic Inhibition

Pancreatic Cells

Synovial Sarcomas

Combinatorial Libraries

Dimerizing Agents

Sonic Hedgehog Modulators

Epigenetic Mechanisms

Deacetylase Inhibitors

71 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12152008 - Cyclopentaimidazolones for the treatment of cancer (2024-11-26),

2. 11382908 - Compositions and methods for treating inflammatory bowel disease (2022-07-12),

3. 11247970 - Selective inhibition of gluconeogenic activity (2022-02-15),

4. 10851051 - Compositions and methods for treating multiple myeloma (2020-12-01),

5. 10752628 - Compounds and methods for treating synovial sarcomas (2020-08-25),

6. 10265321 - Uses of salt-inducible kinase (SIK) inhibitors (2019-04-23),

7. 10172905 - Treatment of protein degradation disorders (2019-01-08),

8. 9944633 - Compounds and methods for the treatment of isocitrate dehydrogenase related diseases (2018-04-17),

9. 9572854 - Treatment of protein degradation disorders (2017-02-21),

10. 9434686 - Deacetylase inhibitors and uses thereof (2016-09-06),

11. 9157062 - Compositions and methods for promoting the generation of PDX1+ pancreatic cells (2015-10-13),

12. 9120810 - Compounds and methods for the treatment of isocitrate dehydrogenase related diseases (2015-09-01),

13. 9108923 - Compounds, compositions, and methods for cancer therapy (2015-08-18),

14. 8999289 - Treatment of protein degradation disorders (2015-04-07),

15. 8951938 - Combinatorial rosamine library to detect cell-state switching (2015-02-10),

Title: The Innovative Journey of Stuart L. Schreiber

Introduction: Stuart L. Schreiber is a renowned inventor based in Boston, MA, known for his groundbreaking contributions to the field of science and technology.

Latest Patents: Stuart L. Schreiber holds several patents in the areas of biotechnology, pharmaceuticals, and chemical biology, showcasing his continuous commitment to innovation.

Career Highlights: With a distinguished career spanning decades, Stuart L. Schreiber has made significant advancements in drug discovery and development, earning him recognition as a pioneer in the industry.

Collaborations: Throughout his career, Stuart L. Schreiber has collaborated with leading researchers, scientists, and institutions worldwide, fostering a culture of innovation and knowledge sharing.

Conclusion: Stuart L. Schreiber's passion for pushing the boundaries of scientific discovery has solidified his reputation as a trailblazing inventor, inspiring the next generation of innovators to continue pushing the frontiers of technology.